Opiant Pharmaceuticals Stock Price, News & Analysis (NASDAQ:OPNT)

$30.89 -2.27 (-6.85 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$33.16
Today's Range$30.50 - $33.72
52-Week Range$5.00 - $51.90
Volume50,673 shs
Average Volume35,751 shs
Market Capitalization$70.62 million
P/E Ratio11.99
Dividend YieldN/A
Beta-1.2

About Opiant Pharmaceuticals (NASDAQ:OPNT)

Opiant Pharmaceuticals logoOpiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.


Industry, Sector and Symbol:
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:OPNT
  • CUSIP: N/A
  • Web: www.opiant.com
Debt:
  • Current Ratio: 2.59%
  • Quick Ratio: 2.59%
Price-To-Earnings:
  • Trailing P/E Ratio: 11.99
  • Forward P/E Ratio: -6.03
Sales & Book Value:
  • Annual Sales: $18.45 million
  • Price / Sales: 3.42
  • Cash Flow: $2.90 per share
  • Price / Cash: 10.66
  • Book Value: $2.14 per share
  • Price / Book: 14.43
Profitability:
  • Trailing EPS: $2.89
  • Net Income: $6.58 million
  • Net Margins: 35.68%
  • Return on Equity: 278.86%
  • Return on Assets: 74.01%
Misc:
  • Employees: 11
  • Outstanding Shares: 2,040,000
 
Frequently Asked Questions for Opiant Pharmaceuticals (NASDAQ:OPNT)

What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced its quarterly earnings data on Friday, October, 13th. The technology company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.87) by $0.70. The technology company earned $3.77 million during the quarter. Opiant Pharmaceuticals had a return on equity of 278.86% and a net margin of 35.68%. View Opiant Pharmaceuticals' Earnings History.

Who are some of Opiant Pharmaceuticals' key competitors?

Who are Opiant Pharmaceuticals' key executives?

Opiant Pharmaceuticals' management team includes the folowing people:

  • Michael J. Sinclair, Executive Chairman of the Board (Age 73)
  • Roger Crystal, President, Chief Executive Officer, Director (Age 38)
  • David D. O'Toole CPA, Chief Financial Officer (Age 58)
  • Arvind Agrawal, Executive Vice President - Medical Affairs
  • Phil Skolnick Ph.D., Chief Scientific Officer (Age 69)
  • Ann L. MacDougall, Director
  • Gabrielle Alison Silver, Director (Age 42)
  • Thomas T. Thomas, Director
  • Geoffrey Wolf, Director (Age 61)

How do I buy Opiant Pharmaceuticals stock?

Shares of Opiant Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Opiant Pharmaceuticals' stock price today?

One share of Opiant Pharmaceuticals stock can currently be purchased for approximately $30.89.

How big of a company is Opiant Pharmaceuticals?

Opiant Pharmaceuticals has a market capitalization of $70.62 million and generates $18.45 million in revenue each year. The technology company earns $6.58 million in net income (profit) each year or $2.89 on an earnings per share basis. Opiant Pharmaceuticals employs 11 workers across the globe.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 201 SANTA MONICA BOULEVARD SUITE 500, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at investor.relations@opiant.com.


MarketBeat Community Rating for Opiant Pharmaceuticals (NASDAQ OPNT)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Opiant Pharmaceuticals (NASDAQ:OPNT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A
Consensus Price Target History for Opiant Pharmaceuticals (NASDAQ:OPNT)
Price Target History for Opiant Pharmaceuticals (NASDAQ:OPNT)
Analysts' Ratings History for Opiant Pharmaceuticals (NASDAQ:OPNT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/26/2015Evercore ISILower Price TargetOutperform$42.00 -> $32.00N/AView Rating Details
11/26/2015B. RileyUpgradeNeutral -> BuyN/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Opiant Pharmaceuticals (NASDAQ:OPNT)
Earnings by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)
Earnings History by Quarter for Opiant Pharmaceuticals (NASDAQ OPNT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/13/2017Q4 2017($0.87)($0.17)$3.77 millionViewN/AView Earnings Details
6/14/2017Q3 2017($0.82)($1.55)$0.02 millionViewN/AView Earnings Details
8/7/2012$0.19$0.21ViewN/AView Earnings Details
5/14/2012$0.20$0.21ViewN/AView Earnings Details
2/7/2012$0.29$0.26ViewN/AView Earnings Details
11/9/2011$0.24$0.24ViewN/AView Earnings Details
8/2/2011$0.15$0.21ViewN/AView Earnings Details
5/9/2011$0.19$0.20ViewN/AView Earnings Details
1/27/2011$0.16$0.23ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Opiant Pharmaceuticals (NASDAQ:OPNT)
2018 EPS Consensus Estimate: ($5.11)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.19)($1.19)($1.19)
Q2 20181($1.24)($1.24)($1.24)
Q3 20181($1.27)($1.27)($1.27)
Q4 20181($1.41)($1.41)($1.41)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Opiant Pharmaceuticals (NASDAQ:OPNT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Opiant Pharmaceuticals (NASDAQ OPNT)
Insider Ownership Percentage: 63.82%
Institutional Ownership Percentage: 0.01%
Insider Trades by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)
Insider Trades by Quarter for Opiant Pharmaceuticals (NASDAQ OPNT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/17/2017Michael SinclairInsiderBuy3,500$7.01$24,535.00View SEC Filing  
1/17/2017Roger CrystalCEOBuy3,475$6.99$24,290.25View SEC Filing  
1/13/2017Kevin PollackInsiderBuy4,820$6.98$33,643.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Opiant Pharmaceuticals (NASDAQ:OPNT)
Latest Headlines for Opiant Pharmaceuticals (NASDAQ OPNT)
Source:
DateHeadline
Critical Review: ChemoCentryx (CCXI) vs. Opiant Pharmaceuticals (OPNT)Critical Review: ChemoCentryx (CCXI) vs. Opiant Pharmaceuticals (OPNT)
www.americanbankingnews.com - November 8 at 5:31 PM
Zacks: Brokerages Expect Opiant Pharmaceuticals, Inc. (OPNT) Will Post Earnings of -$1.19 Per ShareZacks: Brokerages Expect Opiant Pharmaceuticals, Inc. (OPNT) Will Post Earnings of -$1.19 Per Share
www.americanbankingnews.com - October 29 at 3:32 AM
22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency - Benzinga22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency - Benzinga
www.benzinga.com - October 28 at 11:38 AM
A Look At Opiant Pharmaceuticals, The Stock That Skyrocketed On Trumps Opioid DeclarationA Look At Opiant Pharmaceuticals, The Stock That Skyrocketed On Trump's Opioid Declaration
www.benzinga.com - October 27 at 9:12 AM
Comparing Opiant Pharmaceuticals (OPNT) and Tokai Pharmaceuticals (NVUS)Comparing Opiant Pharmaceuticals (OPNT) and Tokai Pharmaceuticals (NVUS)
www.americanbankingnews.com - October 25 at 4:12 PM
Opiant Pharmaceuticals, Inc. (OPNT) Rating Increased to Strong-Buy at ValuEngineOpiant Pharmaceuticals, Inc. (OPNT) Rating Increased to Strong-Buy at ValuEngine
www.americanbankingnews.com - October 21 at 10:40 AM
FY2018 EPS Estimates for Opiant Pharmaceuticals, Inc. (OPNT) Decreased by AnalystFY2018 EPS Estimates for Opiant Pharmaceuticals, Inc. (OPNT) Decreased by Analyst
www.americanbankingnews.com - October 19 at 2:28 PM
Analysts Issue Forecasts for Opiant Pharmaceuticals, Inc.s Q1 2018 Earnings (OPNT)Analysts Issue Forecasts for Opiant Pharmaceuticals, Inc.'s Q1 2018 Earnings (OPNT)
www.americanbankingnews.com - October 18 at 11:30 AM
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q4, 2017 By the Numbers : October 17, 2017Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q4, 2017 By the Numbers : October 17, 2017
finance.yahoo.com - October 18 at 8:02 AM
OPNT: Looking to Keep Momentum Going into Fiscal 2018OPNT: Looking to Keep Momentum Going into Fiscal 2018
finance.yahoo.com - October 17 at 5:30 AM
Critical Review: Kadmon Holdings (KDMN) & Opiant Pharmaceuticals (OPNT)Critical Review: Kadmon Holdings (KDMN) & Opiant Pharmaceuticals (OPNT)
www.americanbankingnews.com - October 15 at 12:22 PM
Opiant Pharmaceuticals, Inc. (OPNT) Announces Quarterly  Earnings ResultsOpiant Pharmaceuticals, Inc. (OPNT) Announces Quarterly Earnings Results
www.americanbankingnews.com - October 14 at 10:00 AM
Is It Time To Buy Opiant Pharmaceuticals Inc (OPNT) Based Off Its PE Ratio?Is It Time To Buy Opiant Pharmaceuticals Inc (OPNT) Based Off Its PE Ratio?
finance.yahoo.com - October 14 at 6:29 AM
Opiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdateOpiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - October 13 at 7:46 AM
Opiant Pharmaceuticals, Inc. (OPNT) Expected to Post Earnings of -$0.87 Per ShareOpiant Pharmaceuticals, Inc. (OPNT) Expected to Post Earnings of -$0.87 Per Share
www.americanbankingnews.com - October 9 at 10:22 PM
Reviewing Opiant Pharmaceuticals (OPNT) and Tokai Pharmaceuticals (NVUS)Reviewing Opiant Pharmaceuticals (OPNT) and Tokai Pharmaceuticals (NVUS)
www.americanbankingnews.com - October 8 at 12:22 AM
Opiant Pharmaceuticals (OPNT) and Strongbridge Biopharma PLC (SBBP) Head to Head ReviewOpiant Pharmaceuticals (OPNT) and Strongbridge Biopharma PLC (SBBP) Head to Head Review
www.americanbankingnews.com - October 4 at 10:26 PM
Opiant Pharmaceuticals and Titan Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder ... - GlobeNewswire (press release)Opiant Pharmaceuticals and Titan Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder ... - GlobeNewswire (press release)
globenewswire.com - October 2 at 8:44 PM
Opiant Pharmaceuticals, Inc., CEO Roger Crystal, M.D., to Present to Presidents Commission on Combating Drug Addiction and the Opioid CrisisOpiant Pharmaceuticals, Inc., CEO Roger Crystal, M.D., to Present to President's Commission on Combating Drug Addiction and the Opioid Crisis
finance.yahoo.com - October 1 at 6:11 PM
Pharma execs urge quicker FDA approval for opioid alternatives - USA TODAYPharma execs urge quicker FDA approval for opioid alternatives - USA TODAY
www.usatoday.com - September 29 at 12:47 PM
Opiant Up Nearly 30% On Favorable Zachs ReportOpiant Up Nearly 30% On Favorable Zachs Report
finance.yahoo.com - September 22 at 7:33 AM
Critical Review: Opiant Pharmaceuticals (OPNT) & MediWound (MDWD)Critical Review: Opiant Pharmaceuticals (OPNT) & MediWound (MDWD)
www.americanbankingnews.com - September 22 at 6:32 AM
 Analysts Expect Opiant Pharmaceuticals, Inc. (OPNT) to Announce -$0.87 EPS Analysts Expect Opiant Pharmaceuticals, Inc. (OPNT) to Announce -$0.87 EPS
www.americanbankingnews.com - September 21 at 10:14 AM
OPNT: Estimating When Royalties to NARCAN® Nasal Spray Revert Back to OpiantOPNT: Estimating When Royalties to NARCAN® Nasal Spray Revert Back to Opiant
finance.yahoo.com - September 20 at 7:25 AM
Clovis Up 10% On Double Normal Volume - Forbes - ForbesClovis Up 10% On Double Normal Volume - Forbes - Forbes
www.forbes.com - September 19 at 6:14 AM
Corporate News Blog - Opiant Delivers Update on NARCAN Nasal Spray; Surpasses $25 Million Net Sales in H1 2017Corporate News Blog - Opiant Delivers Update on NARCAN Nasal Spray; Surpasses $25 Million Net Sales in H1 2017
finance.yahoo.com - September 19 at 6:14 AM
Opiant bullish on opioid antagonist Narcan - Seeking AlphaOpiant bullish on opioid antagonist Narcan - Seeking Alpha
seekingalpha.com - September 17 at 11:38 PM
Opiant Pharmaceuticals, Inc. Provides an Update on NARCAN® Nasal SprayOpiant Pharmaceuticals, Inc. Provides an Update on NARCAN® Nasal Spray
finance.yahoo.com - September 15 at 7:16 AM
Analyzing Opiant Pharmaceuticals (OPNT) and its CompetitorsAnalyzing Opiant Pharmaceuticals (OPNT) and its Competitors
www.americanbankingnews.com - September 12 at 2:26 AM
Opnet Technologies, Inc. (OPNT) Appoints David OToole as CFOOpnet Technologies, Inc. (OPNT) Appoints David O'Toole as CFO
www.streetinsider.com - September 6 at 7:14 AM
Opiant Pharmaceuticals, Inc. Announces Appointment of David O’Toole as Chief Financial OfficerOpiant Pharmaceuticals, Inc. Announces Appointment of David O’Toole as Chief Financial Officer
finance.yahoo.com - September 6 at 7:14 AM
Opiant Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 19th Annual Global Investment ConferenceOpiant Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 6 at 7:14 AM
 Brokerages Anticipate Opiant Pharmaceuticals, Inc. (OPNT) to Announce -$0.87 Earnings Per Share Brokerages Anticipate Opiant Pharmaceuticals, Inc. (OPNT) to Announce -$0.87 Earnings Per Share
www.americanbankingnews.com - September 2 at 6:30 PM
OPNT: Uplists to NASDAQOPNT: Uplists to NASDAQ
finance.yahoo.com - August 30 at 7:39 AM
Analysts Expect Opiant Pharmaceuticals Inc (OPNT) to Post ($0.87) Earnings Per ShareAnalysts Expect Opiant Pharmaceuticals Inc (OPNT) to Post ($0.87) Earnings Per Share
www.americanbankingnews.com - August 29 at 8:50 PM
Opiant Pharmaceuticals, Inc. Announces Listing on the Nasdaq Capital MarketOpiant Pharmaceuticals, Inc. Announces Listing on the Nasdaq Capital Market
finance.yahoo.com - August 29 at 6:22 AM
Opiant Pharmaceuticals (OPNT) & Sabre Corporation (SABR) Critical ReviewOpiant Pharmaceuticals (OPNT) & Sabre Corporation (SABR) Critical Review
www.americanbankingnews.com - August 18 at 2:26 PM
 Brokerages Expect Opiant Pharmaceuticals Inc (NASDAQ:OPNT) to Announce -$0.87 Earnings Per Share Brokerages Expect Opiant Pharmaceuticals Inc (NASDAQ:OPNT) to Announce -$0.87 Earnings Per Share
www.americanbankingnews.com - August 15 at 6:30 AM
Opiant CEO Roger Crystal Appears on Fox News Channel to Discuss the Opioid Crisis Being Declared a National EmergencyOpiant CEO Roger Crystal Appears on Fox News Channel to Discuss the Opioid Crisis Being Declared a National Emergency
finance.yahoo.com - August 15 at 5:50 AM
 Opiant Pharmaceuticals Inc (OPNT) Given Consensus Recommendation of "" by Brokerages Opiant Pharmaceuticals Inc (OPNT) Given Consensus Recommendation of "" by Brokerages
www.americanbankingnews.com - August 14 at 6:38 AM
OPNT: Receives Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty MonetizationOPNT: Receives Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization
finance.yahoo.com - August 12 at 6:39 AM
Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty MonetizationOpiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization
finance.yahoo.com - August 11 at 7:18 AM
 Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Receives Consensus Recommendation of "" from Brokerages Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Receives Consensus Recommendation of "" from Brokerages
www.americanbankingnews.com - August 10 at 5:16 PM
Opiant Pharmaceuticals Looks to Create a Heroin Vaccine and Treat AddictionsOpiant Pharmaceuticals Looks to Create a Heroin Vaccine and Treat Addictions
finance.yahoo.com - July 29 at 6:03 AM
 Analysts Anticipate Opiant Pharmaceuticals Inc (OPNT) to Post -$0.87 EPS Analysts Anticipate Opiant Pharmaceuticals Inc (OPNT) to Post -$0.87 EPS
www.americanbankingnews.com - July 28 at 9:38 AM
Opiant CEO Roger Crystal Appears on Fox & FriendsOpiant CEO Roger Crystal Appears on Fox & Friends
finance.yahoo.com - July 28 at 6:30 AM
Opiant CEO Roger Crystal Appears on Fox Business NetworkOpiant CEO Roger Crystal Appears on Fox Business Network
finance.yahoo.com - July 27 at 6:07 AM
OPNT: Encouraging Data From P1 Study of OPNT002 in Alcohol Use DisorderOPNT: Encouraging Data From P1 Study of OPNT002 in Alcohol Use Disorder
finance.yahoo.com - July 21 at 5:38 AM
 Analysts Anticipate Opiant Pharmaceuticals Inc (OPNT) Will Announce Earnings of -$0.87 Per Share Analysts Anticipate Opiant Pharmaceuticals Inc (OPNT) Will Announce Earnings of -$0.87 Per Share
www.americanbankingnews.com - July 3 at 10:22 PM
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsOPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
biz.yahoo.com - March 16 at 7:48 PM

Social Media

Financials

Chart

Opiant Pharmaceuticals (NASDAQ OPNT) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.